These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 28349274)

  • 1. A Systematic Review of Add-on Pharmacologic Therapy in the Treatment of Resistant Hypertension.
    Tataru AP; Barry AR
    Am J Cardiovasc Drugs; 2017 Aug; 17(4):311-318. PubMed ID: 28349274
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological interventions for hypertension in children.
    Chaturvedi S; Lipszyc DH; Licht C; Craig JC; Parekh R
    Cochrane Database Syst Rev; 2014 Feb; 2014(2):CD008117. PubMed ID: 24488616
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological interventions for hypertension in children.
    Chaturvedi S; Lipszyc DH; Licht C; Craig JC; Parekh R
    Evid Based Child Health; 2014 Sep; 9(3):498-580. PubMed ID: 25236305
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cochrane in context: pharmacological interventions for hypertension in children.
    Chaturvedi S; Lipszyc DH; Licht C; Craig JC; Parekh RS
    Evid Based Child Health; 2014 Sep; 9(3):581-3. PubMed ID: 25236306
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low-dose and very low-dose spironolactone in combination therapy for essential hypertension: evaluation by self-measurement of blood pressure at home.
    Hanazawa T; Obara T; Ogasawara K; Shinki T; Katada S; Inoue R; Metoki H; Asayama K; Kikuya M; Ohkubo T; Mano N; Imai Y
    Clin Exp Hypertens; 2011; 33(7):427-36. PubMed ID: 21777149
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Addition of spironolactone in patients with resistant hypertension: A meta-analysis of randomized controlled trials.
    Liu L; Xu B; Ju Y
    Clin Exp Hypertens; 2017; 39(3):257-263. PubMed ID: 28448185
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blood pressure lowering efficacy of loop diuretics for primary hypertension.
    Musini VM; Rezapour P; Wright JM; Bassett K; Jauca CD
    Cochrane Database Syst Rev; 2012 Aug; (8):CD003825. PubMed ID: 22895937
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Time course for blood pressure lowering of dihydropyridine calcium channel blockers.
    Ghamami N; Chiang SH; Dormuth C; Wright JM
    Cochrane Database Syst Rev; 2014 Aug; 2014(8):CD010052. PubMed ID: 25173808
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A meta-analysis of add-on use of spironolactone in patients with resistant hypertension.
    Zhao D; Liu H; Dong P; Zhao J
    Int J Cardiol; 2017 Apr; 233():113-117. PubMed ID: 28089457
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [PATHWAY-2 Study: spironolactone vs placebo, bisoprolol and doxazosin to determine optimal treatment of resistant hypertension. Spironolactone high effective in lowering blood pressure in drug resistant hypertension].
    Widimský J
    Vnitr Lek; 2015 Dec; 61(12):1067-71. PubMed ID: 26806502
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blood pressure lowering efficacy of loop diuretics for primary hypertension.
    Musini VM; Wright JM; Bassett K; Jauca CD
    Cochrane Database Syst Rev; 2009 Oct; (4):CD003825. PubMed ID: 19821314
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Spironolactone and doxazosin treatment in patients with resistant hypertension.
    Rodilla E; Costa JA; Pérez-Lahiguera F; Baldó E; González C; Pascual JM
    Rev Esp Cardiol; 2009 Feb; 62(2):158-66. PubMed ID: 19232189
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT): a randomized, double-blind, placebo-controlled trial.
    Václavík J; Sedlák R; Plachy M; Navrátil K; Plásek J; Jarkovsky J; Václavík T; Husár R; Kociánová E; Táborsky M
    Hypertension; 2011 Jun; 57(6):1069-75. PubMed ID: 21536989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of spironolactone in patients with resistant arterial hypertension in relation to baseline blood pressure and secondary causes of hypertension.
    Vaclavik J; Sedlak R; Jarkovsky J; Kocianova E; Taborsky M
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2013 Mar; 157(1):50-5. PubMed ID: 23128822
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low-dose spironolactone reduces plasma fibulin-1 levels in patients with type 2 diabetes and resistant hypertension.
    Oxlund CS; Cangemi C; Henriksen JE; Jacobsen IA; Gram J; Schousboe K; Tarnow L; Argraves WS; Rasmussen LM
    J Hum Hypertens; 2015 Jan; 29(1):28-32. PubMed ID: 24739800
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and Safety of Spironolactone in Patients with Resistant Hypertension: A Meta-analysis of Randomised Controlled Trials.
    Wang C; Xiong B; Huang J
    Heart Lung Circ; 2016 Oct; 25(10):1021-30. PubMed ID: 27118266
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Using fixed-dose combination therapies to achieve blood pressure goals.
    Chrysant SG
    Clin Drug Investig; 2008; 28(11):713-34. PubMed ID: 18840014
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Spironolactone Versus Clonidine as a Fourth-Drug Therapy for Resistant Hypertension: The ReHOT Randomized Study (Resistant Hypertension Optimal Treatment).
    Krieger EM; Drager LF; Giorgi DMA; Pereira AC; Barreto-Filho JAS; Nogueira AR; Mill JG; Lotufo PA; Amodeo C; Batista MC; Bodanese LC; Carvalho ACC; Castro I; Chaves H; Costa EAS; Feitosa GS; Franco RJS; Fuchs FD; Guimarães AC; Jardim PC; Machado CA; Magalhães ME; Mion D; Nascimento RM; Nobre F; Nóbrega AC; Ribeiro ALP; Rodrigues-Sobrinho CR; Sanjuliani AF; Teixeira MDCB; Krieger JE;
    Hypertension; 2018 Apr; 71(4):681-690. PubMed ID: 29463627
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Spironolactone and chlorthalidone in uncontrolled elderly hypertensive patients treated with calcium antagonists and angiotensin II receptor-blocker: effects on endothelial function, inflammation, and oxidative stress.
    Yamanari H; Nakamura K; Miura D; Yamanari S; Ohe T
    Clin Exp Hypertens; 2009 Oct; 31(7):585-94. PubMed ID: 19886856
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies.
    Williams B; MacDonald TM; Morant SV; Webb DJ; Sever P; McInnes GT; Ford I; Cruickshank JK; Caulfield MJ; Padmanabhan S; Mackenzie IS; Salsbury J; Brown MJ;
    Lancet Diabetes Endocrinol; 2018 Jun; 6(6):464-475. PubMed ID: 29655877
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.